{
    "clinical_study": {
        "@rank": "28441", 
        "arm_group": {
            "arm_group_label": "GP2013", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate safety and pharmacokinetic of GP2013 in Japanese\n      patients with CD20 positive low tumor burden indolent B-cell NHL under weekly dosing\n      schedule."
        }, 
        "brief_title": "GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Indolent B-cell Non-Hodgkin's Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, B-Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient with CD20 positive low tumor burden indolent B-cell non- Hodgkin's lymphoma.\n\n          -  Patient with at least one measurable lesion.\n\n          -  Patient with ECOG performance status 0 or 1.\n\n        Exclusion Criteria:\n\n          -  Patient who has received radiotherapy within the last 28 days prior to\n             administration, or are not recovered from previous radiotherapy.\n\n          -  Patient who has received immunotherapy, chemotherapy, antibodies and experimental\n             treatment within the last 28 days prior to administration, or are not recovered from\n             previous therapy.\n\n          -  Patient who has mAb therapy other than rituximab as prior line of therapy.\n\n          -  Patient with evidence of any uncontrolled, acute or chronic active infection (viral,\n             bacterial or fungal).\n\n          -  Patient with any other malignancy within 5 years prior to date of screening, with the\n             exception of adequately treated in situ carcinoma of the cervix uteri, basal or\n             squamous cell carcinoma or nonmelanomatous skin cancer.\n\n        Other protocol-defined inclusion/exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01933516", 
            "org_study_id": "GP13-101"
        }, 
        "intervention": {
            "arm_group_label": "GP2013", 
            "description": "GP2013", 
            "intervention_name": "GP2013", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "GP2013", 
            "Japanese", 
            "indolent B-cell non-Hodgkin's lymphoma", 
            "biosimilar", 
            "CD20", 
            "GP13-101"
        ], 
        "lastchanged_date": "August 28, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tachikawa", 
                    "country": "Japan", 
                    "state": "Tokyo", 
                    "zip": "190-0014"
                }, 
                "name": "Investigative Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Trial to Assess the Safety and Pharmacokinetics of GP2013 Monotherapy Administered Weekly in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma", 
        "overall_contact": {
            "last_name": "Sandoz K.K.", 
            "phone": "+81-3-5469-3101"
        }, 
        "overall_official": {
            "affiliation": "Sandoz K.K.", 
            "last_name": "Sandoz K.K.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Adverse events, laboratory abnormalities", 
                "measure": "To evaluate safety of GP2013", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Area under the curve calculated from start of dose to the end of the dosing interval (tau) of GP2013", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Maximum observed concentration of GP2013", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Time to reach maximum concentration of GP2013", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Minimum (trough) observed concentration during each dosing interval of GP2013", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Terminal elimination rate constant calculated as the slope of the linear regression of the terminal phase of the logarithmic concentration-time profile of GP2013", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Elimination half-life associated with the terminal slope of GP2013", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01933516"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Antitumor activity", 
                "measure": "To evaluate efficacy of GP2013", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Immunogenicity (ADA formation)", 
                "measure": "To evaluate the incidence of immunogenicity (ADA formation) against GP2013", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "CD19 + B-cell count", 
                "measure": "To evaluate peripheral CD19+ B-cell count", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Sandoz K.K.", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Sandoz K.K.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}